Richard P. Baum
Goethe University Frankfurt
Internal medicineRadiologyPET-CTPathologyOncologyChemistryPositron emission tomographySomatostatinImmunoscintigraphyNeuroendocrine tumorsScintigraphyProstate cancerNuclear medicineRadionuclide therapyPeptide receptorCancer researchRadiation therapyMonoclonal antibodyMedicineSomatostatin receptorGastroenterology
Publications 378
#1Jingjing Zhang (NUS: National University of Singapore)
#2Harshad R. KulkarniH-Index: 26
Last. Richard P. BaumH-Index: 63
view all 3 authors...
ABSTRACT Somatostatin receptor-targeted α-therapy using α-emitter 225Ac-labeled somatostatin analogs has been suggested as a treatment option in advanced metastatic neuroendocrine tumors (NETs) failing treatment with β-emitters, such as 177Lu or 90Y. Thymus NETs are rare and usually more aggressive than other neuroendocrine tumor entities. We present here a case with β-radiation refractory metastatic thymus NET, who demonstrated an excellent therapy response (molecular and morphological remissio...
#2Matthias TwrznikH-Index: 1
#3Harshad R. KulkarniH-Index: 26
Last. Merten HommannH-Index: 20
view all 7 authors...
MINI: The role of resection of primary tumors in patients with advanced neuroendocrine neoplasms is still unclear. We investigated 2 groups of patients treated using peptide receptor radionuclide therapy (PRRT; mean of 4 cycles PRRT) with and without a prior primary tumors resection. Surgical resection resulted in a significantly prolonged overall- and progression-free survival.This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Deriva...
7 CitationsSource
Fibroblast activation protein (FAP) is a promising target for diagnosis and therapy of numerous malignant tumors. FAP-2286 is the conjugate of a FAP-binding peptide, which can be labeled with radionuclides for theranostic applications. We present the first-in-human results using 177Lu-FAP-2286 for peptide-targeted radionuclide therapy (PTRT). Methods: PTRT using 177Lu-FAP-2286 was performed in 11 patients with advanced adenocarcinomas of pancreas, breast, rectum and ovary after prior confirmatio...
1 CitationsSource
#1Hojjat Ahmadzadehfar (University Hospital Bonn)H-Index: 36
#2Ralf Matern (University Hospital Bonn)H-Index: 1
Last. Kambiz RahbarH-Index: 22
view all 19 authors...
INTRODUCTION Prostate-specific membrane antigen (PSMA)-based radioligand therapy (RLT) showed in a multicentre WARMTH (World Association of Radiopharmaceutical and Molecular Therapy) study that the presence of bone metastases is a negative prognosticator for the survival. The current multicentre retrospective analysis aims to evaluate the response rate to RLT, the overall survival (OS) of patients and the safety of the treatment according to the extent of bone involvement. METHODS The study incl...
2 CitationsSource
#1M. Chantadisai (Chula: Chulalongkorn University)H-Index: 1
#2Harshad R. KulkarniH-Index: 26
Last. Richard P. BaumH-Index: 63
view all 3 authors...
To determine prognostic factors and overall survival (OS) in therapy-related myeloid neoplasm (t-MN) of patients after receiving peptide receptor radionuclide therapy (PRRT). All patients treated from February 1999 until September 2019 at our center who had bone marrow biopsy-proven t-MN after PRRT were included. Patient characteristics, laboratory results, and all tumor-directed therapies before t-MN diagnosis were collected. Cox regression analysis was performed to identify parameters associat...
2 CitationsSource
#1Jonathan Strosberg (Moffitt Cancer Center)H-Index: 12
#2Rajaventhan Srirajaskanthan (University of Cambridge)H-Index: 10
Last. Eric P. Krenning (Erasmus University Medical Center)H-Index: 116
view all 16 authors...
We report the impact of 177Lu DOTATATE treatment on abdominal pain, diarrhea, and flushing, symptoms that patients with advanced midgut neuroendocrine tumors (NETs) often find burdensome. Methods: All patients enrolled in the international randomized phase 3 Neuroendocrine Tumors Therapy (NETTER-1) trial (177Lu-DOTATATE plus standard-dose octreotide long-acting repeatable [LAR], n = 117; high-dose octreotide LAR, n = 114) were asked to record the occurrence of predefined symptoms in a daily diar...
#1Andrea Frilling (Imperial College London)H-Index: 19
#2Ashley K. Clift (Imperial College London)H-Index: 13
Last. Richard P. BaumH-Index: 63
view all 11 authors...
Rationale: Neuroendocrine neoplasia (NEN) of small bowel (SBNEN) frequently present with metastatic disease. Theranostics (molecular imaging followed by targeting therapy) allow for personalised medicine. Liquid biopsies enable precise identification of residual disease and real-time monitoring of therapeutic response. Our aim was to determine the clinical utility of a combination of surgery, theranostics, and a multigene blood measurement in metastasised SBNEN. Methods: Inclusion criteria were ...
1 CitationsSource
#1Richard P. BaumH-Index: 63
#2Jingjing ZhangH-Index: 15
Last. Helmut R. MaeckeH-Index: 59
view all 5 authors...
The objective of this study was to assess the safety, dosimetry, and efficacy of the 177Lu-labeled somatostatin receptor (SSTR) antagonist DOTA-p-Cl-Phe-cyclo (D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr-NH2 (177Lu-DOTA-LM3) in patients with metastatic neuroendocrine neoplasms (NENs). Methods: Fifty-one patients (age 27-76, mean 51.6±13.9 years) with metastatic NENs underwent peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTA-LM3 between August 2017 and December 2019. The medi...
3 CitationsSource
#1Richard P. BaumH-Index: 63
#2Aviral SinghH-Index: 56
Last. Cristina Müller (Paul Scherrer Institute)H-Index: 38
view all 15 authors...
161Tb has similar decay properties as 177Lu but, additionally, emits a substantial number of conversion and Auger electrons. The aim of this study was to apply 161Tb in a clinical setting and to investigate the feasibility to visualize the physiological and tumor biodistribution of 161Tb-DOTATOC. Methods:161Tb was shipped from Paul Scherrer Institute, Switzerland, to Zentralklinik Bad Berka, Germany, where it was used for the radiolabeling of DOTATOC. In two separate studies, 596 MBq and 1300 MB...
6 CitationsSource